These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19244114)

  • 1. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
    Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P
    Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG.
    Hadley KE; Hendricks DT
    BMC Cancer; 2014 May; 14():334. PubMed ID: 24886060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
    Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
    Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
    Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
    Kasai S; Arakawa N; Okubo A; Shigeeda W; Yasuhira S; Masuda T; Akasaka T; Shibazaki M; Maesawa C
    PLoS One; 2016; 11(4):e0153181. PubMed ID: 27045471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aryl hydrocarbon receptor is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells.
    Chen PH; Chang JT; Li LA; Tsai HT; Shen MY; Lin P
    Mol Pharmacol; 2013 Mar; 83(3):605-12. PubMed ID: 23229511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
    McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
    Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
    Siegel D; Shieh B; Yan C; Kepa JK; Ross D
    J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?
    Mayor-López L; Tristante E; Carballo-Santana M; Carrasco-García E; Grasso S; García-Morales P; Saceda M; Luján J; García-Solano J; Carballo F; de Torre C; Martínez-Lacaci I
    Transl Oncol; 2014 Oct; 7(5):590-604. PubMed ID: 25389454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
    Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
    Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
    Siegel D; Yan C; Ross D
    Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
    Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
    Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
    Douglas M; Lim AR; Porter JR; West K; Pink MM; Ge J; Wylie AA; Tibbits TT; Biggs K; Curtis M; Palombella VJ; Adams J; Fritz CC; Normant E
    Mol Cancer Ther; 2009 Dec; 8(12):3369-78. PubMed ID: 19952119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hsp90: small-molecule inhibitors and their clinical development.
    Taldone T; Gozman A; Maharaj R; Chiosis G
    Curr Opin Pharmacol; 2008 Aug; 8(4):370-4. PubMed ID: 18644253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
    Li Y; Zhang T; Schwartz SJ; Sun D
    Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Mol Pharmacol; 2006 Oct; 70(4):1194-203. PubMed ID: 16825487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.